Invacare CEO to depart after poor Q2
This article was originally published in Clinica
Long-term care products specialist Invacare president and CEO Gerald Blouch is to retire after 24 years with the company, following a disappointing second quarter. Chief financial officer Robert Gudbranson will lead the firm on an interim basis while it searches for a permanent replacement. Invacare’s Q2 sales slumped 4% year-on-year to $331.3m, while net loss widened to $13.6m, from $12.5m in Q2 2013. “The strong performance of the European business was more than offset by the weak financial results of the North America/home medical equipment and Asia/Pacific segments,” Mr Blouch stated. “Clearly, Invacare's businesses outside of Europe are under pressure, and we are not pleased with the second quarter's consolidated financial results.” The firm’s shares plunged 15% to close at $14.96 on 24 July, the day it announced the news.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.